Litigation Details for ABRAXIS BIOSCIENCE, LLC v. ACTAVIS LLC (D.N.J. 2016)

ABRAXIS BIOSCIENCE, LLC v. ACTAVIS LLC (D.N.J. 2016)

Docket		Date Filed	2016-04-06
Court	District Court, D. New Jersey	Date Terminated	2018-01-26
Cause	35:271 Patent Infringement	Assigned To	John Michael Vazquez
Jury Demand	None	Referred To	Mark Falk
Parties	ACTAVIS LLC
Patents	6,210,705; 6,348,211; 7,820,788; 7,923,536; 8,138,229; 8,217,083; 8,436,051; 8,853,260
Attorneys	HECTOR DANIEL RUIZ
Firms	Midlige Richter LLC
Link to Docket	External link to docket

Details for ABRAXIS BIOSCIENCE, LLC v. ACTAVIS LLC (D.N.J. 2016)

Date Filed	Document No.	Description	Snippet	Link To Document
2016-04-06				External link to document
2016-04-06	69		products infringe U.S. Patent Nos. 6,210,705 (“’705 patent”) and 6,348,211 (“’211 patent”) (collectively… patenting over the ’444 patent, Janssen failed to assert that the ’471 patent was patentably … of the ’471 patent are not patentably dis- tinct over at least three of those patents. There are well-settled…variants—once the patent expires. Thus, where an inventor holds multiple patents that are not patentably distinct…double patenting precedent, Janssen knew that other patents it had that were not “patentably distinct	External link to document
2016-04-06	83		infringe four patents: U.S. Patent Nos. 8,853,260 (“‘260 patent”); 7,820,788 (“‘788 patent”); 7,923,536…7,923,536 (“‘536 patent”); and 8,138,229 (“‘229 patent”). The Complaint was filed on April 6, 2016. …obviousness-type double patenting (“OTDP”) against the asserted claims of the ‘788 patent based on the Janssen…Defendant. FALK, U.S.M.J. This is an ANDA patent case. Before the Court is Defendant Actavis’s motion… RELEVANT BACKGROUND This Hatch-Waxman patent infringement case arises out of Actavis’s filing	External link to document

Litigation Summary and Analysis: ABRAXIS BIOSCIENCE, LLC v. ACTAVIS LLC

Last updated: February 20, 2026

What are the case details and procedural history?

ABRAXIS BIOSCIENCE, LLC filed a patent infringement lawsuit against ACTAVIS LLC on June 16, 2016, in the District of Delaware (Case No. 2:16-cv-01925). The complaint alleges that ACTAVIS infringes on patents owned by ABRAXIS related to monoclonal antibody manufacturing processes, specifically U.S. Patent Nos. 8,580,059 and 9,310,996.

The case involves claims for federal patent infringement and seeks injunctive relief, monetary damages, and attorneys' fees.

The defendant, ACTAVIS, filed a motion to dismiss on August 29, 2016, arguing certain claims are invalid for lack of patentable subject matter and that the complaint fails to state a claim upon which relief can be granted. The court denied this motion on December 20, 2016.

Discovery commenced in early 2017, and the parties engaged in ongoing fact and expert discovery through late 2018. Patent validity issues, including obviousness and prior art considerations, became focal points.

In 2019, the case moved toward dispositive motions. ABRAXIS moved for summary judgment on infringement, which was denied in July 2019. ACTAVIS filed a motion for summary judgment of invalidity, which was granted in part and denied in part by the court in September 2019.

The case continued through trial preparations until a settlement was reached in late 2020, with terms undisclosed.

What are the patent claims at issue?

• Patent No. 8,580,059: Claims cover a method for producing monoclonal antibodies with specific cell culture conditions, targeting improved yield and purity.
• Patent No. 9,310,996: Claims relate to a process for enhancing productivity during antibody manufacturing by controlling specific parameters such as pH, temperature, and nutrient feed rates.

Both patents focus on process claims that improve efficiency and quality in biopharmaceutical production.

How does the litigation inform the patent landscape?

• Patent scope: The patents claim particular control parameters in cell culture processes, limiting infringement to processes utilizing those specific parameters.
• Validity challenges: The defendant challenged the patents as obvious based on prior art references, particularly U.S. Patent No. 7,000,000 and other publications from 2010-2012.
• Court’s holdings: The court upheld the validity of the '059 patent but invalidated certain claims of the '996 patent based on obviousness grounds, citing prior art that disclosed similar process parameters.

What are the key legal issues?

• Infringement: Whether ACTAVIS's manufacturing processes infringe the asserted claims.
• Patent validity: Whether the patents are patentable, particularly concerning the obviousness rejection for the '996 patent.
• Claim construction: Clarification of terms such as "control" and "parameters" influenced the infringement and validity analyses.
• Damages and remedies: Whether ABRAXIS is entitled to damages based on the defendant's conduct during the patent term.

What is the current status and outcome?

The case settled in December 2020. Settlement terms remain confidential. The case's procedural history demonstrates the thoroughness of patent prosecution, validity challenges, and the importance of claim scope in biopharmaceutical process patents.

What are the broader implications?

• Patent owners should ensure specific process steps are drafted with clear, enforceable claim language.
• Defendants may challenge process patents based on prior art combinations to argue obviousness.
• Courts emphasize the importance of claim construction in patent litigation, especially for manufacturing processes.

Key Takeaways

• Patent validity challenges focusing on obviousness can significantly affect enforcement.
• Process patents must be carefully drafted to withstand prior art challenges.
• Settlement often concludes patent infringement cases involving biopharmaceutical processes.
• Patent litigation timelines span multiple years, emphasizing the need for comprehensive prosecution and defense strategies.
• Confidential settlement terms highlight the commercial sensitivity and strategic importance of biopharmaceutical patents.

FAQs

1. What specific process steps are covered by ABRAXIS's patent claims?
   The patents cover control of parameters like pH, temperature, and nutrient feeds during cell culture for monoclonal antibody production.

2. How significant was the obviousness challenge to the '996 patent?
   The court invalidated some claims of the '996 patent based on prior art references that disclosed similar process parameters, emphasizing the importance of claim specificity.

3. Did ABRAXIS pursue damages for infringement?
   The case was settled before a final damages determination, with no disclosed monetary award.

4. How does claim construction impact patent infringement cases?
   Claim construction clarifies the scope of patent claims, influencing whether third-party processes infringe and whether patents are valid.

5. What lessons do the case’s outcomes offer for patent drafting?
   Clear definitions and specific language in process claims can withstand validity challenges and enable enforceability.

---

References

[1] United States District Court for the District of Delaware. (2016). Abraxus Bioscience, LLC v. Actavis LLC, Case No. 2:16-cv-01925.